From: Tina_Still@eisai.com
To: AGO - High Cost Prescription Drugs
Subject: New Drug Report pursuant to 18 V.S.A § 4637(c)
Date: Friday, February 17, 2023 10:00:56 AM
Attachments: image003.png

EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.

February 17, 2023

Subject: Notice pursuant to 18 V.S.A § 4637(c)

To Whom It May Concern:

In a follow-up to our notice submitted on January 20, 2023, Eisai Inc. is providing the required report for the release of the new drug LEQEMBI™ into the commercial market pursuant to 18 V.S.A. § 4637(c):

Product Information

NDC Number	Product Description	Date of Commercial Availability	Wholesale Acquisition Cost
62856-0212-01	Leqembi 200mg/2ml	January 18, 2023	$254.81
62856-0215-01	Leqembi 500mg/5ml	January 18, 2023	$637.02

Reporting Requirements

Section 4637 (c) Reporting Requirements	Response for Leqembi™ Injection
1) a description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally;	Marketing Plan - During accelerated approval, Eisai's marketing engagements with healthcare professionals generally will be limited to and focused on understanding how an AD therapy will be integrated into practice. Pricing Plan - Eisai considered a holistic approach in assessing value and making decisions that may affect patient access, so that our LEQEMBI pricing approach can maximize value for all stakeholders (patients, families, caregivers, healthcare

	providers, payers, employees and shareholders). This approach includes clinical outcome assessments of our medicines and the benefits we deliver to patients, their families and caregivers as the "clinical value," as well as the projected "social value" that help improve patients' and caregivers' quality of life and productivity. Moreover, we assess the simulated impact of our medicines on reducing demand for health services and global burden of disease as potential "economic value" while enhancing further innovations in AD. Eisai decided to price LEQEMBI below the quantified societal value. For further details, including Eisai's calculation of the societal value, please see Eisai's press release dated January 6, 2023 titled EISAI'S APPROACH TO U.S. PRICING FOR LEQEMBI™ (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMER'S DISEASE, SETS FORTH OUR CONCEPT OF "SOCIETAL VALUE OF MEDICINE" IN RELATION TO "PRICE OF MEDICINE"
(2) the estimated volume of patients who may be prescribed the drug;	100,000 - Estimated Volume of Patients - "In the U.S., we estimate that the diagnosed eligible Early AD population will reach approximately 100,000 individuals by year 3 representing a measured initial attainment in the real world and will increase gradually over the mid-to-long term given the time required to advance new screening and diagnostic technologies such as blood-based biomarkers to confirm amyloid beta pathology."
(3) whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval; and	Yes
(4) the date and price of acquisition if the drug was not developed by the manufacturer.	N/A

[This e-mail message may contain privileged, confidential and/or proprietary information of Eisai. If you believe that it has been sent to you in error, please contact the sender immediately and delete the message including any attachments, without copying, using, or distributing any of the information contained therein. This e-mail message should not be interpreted to include a digital or electronic signature that can be used to authenticate an agreement, contract or other

legal document, nor to reflect an intention to be bound to any legally-binding agreement or contract.]